NasdaqCM - Delayed Quote • USD
Cellectar Biosciences, Inc. (CLRB)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 7:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | 5 | 2 | 4 | 5 |
| Avg. Estimate | -1 | -0.72 | -3.91 | -2.83 |
| Low Estimate | -1.43 | -0.75 | -4.72 | -5.15 |
| High Estimate | -0.69 | -0.7 | -2.61 | -1.32 |
| Year Ago EPS | -0.9 | -1 | -4.3 | -3.91 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | 3 | 1 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 12/31/2021 | 3/31/2022 | 6/30/2022 | 9/30/2022 |
|---|---|---|---|---|
| EPS Est. | -1.02 | -1 | -1.03 | -1.21 |
| EPS Actual | -0.9 | -1 | -1.22 | -1.28 |
| Difference | 0.12 | 0 | -0.19 | -0.07 |
| Surprise % | 11.80% | 0.00% | -18.40% | -5.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Current Estimate | -1 | -0.72 | -3.91 | -2.83 |
| 7 Days Ago | -1.23 | -0.6 | -4.46 | -2.21 |
| 30 Days Ago | -1.23 | -0.6 | -4.46 | -2.69 |
| 60 Days Ago | -1.13 | 0 | -4.25 | -4.14 |
| 90 Days Ago | -1.13 | 0 | -4.25 | -4.14 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Up Last 7 Days | 3 | -- | 3 | 2 |
| Up Last 30 Days | 3 | -- | 3 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | CLRB | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -11.10% | -- | -- | 0.80% |
| Next Qtr. | 28.00% | -- | -- | 9.60% |
| Current Year | 9.10% | -- | -- | 4.50% |
| Next Year | 27.60% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Roth MKM: Buy to Buy | 3/28/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 3/28/2024 |
| Reiterates | Roth MKM: Buy to Buy | 3/4/2024 |
| Maintains | HC Wainwright & Co.: Buy | 11/4/2022 |
Related Tickers
ASMB Assembly Biosciences, Inc.
13.33
+2.85%
MREO Mereo BioPharma Group plc
2.6500
+2.71%
CTMX CytomX Therapeutics, Inc.
1.7300
-1.70%
SPRO Spero Therapeutics, Inc.
1.4700
-2.00%
NXTC NextCure, Inc.
1.5700
+3.97%
PDSB PDS Biotechnology Corporation
2.9000
+6.62%
CYTK Cytokinetics, Incorporated
67.00
-1.37%
EIGR Eiger BioPharmaceuticals, Inc.
1.7250
0.00%
LVTX LAVA Therapeutics N.V.
2.8300
-3.74%
ALGS Aligos Therapeutics, Inc.
0.7931
+0.78%